Dr. Gomella on Immunotherapy Developments in Prostate Cancer

Video

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy developments for patients with prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy developments for patients with prostate cancer.

The customized immunotherapy that was approved almost 8 years ago, sipuleucel-T (Provenge), continues to be one of the mainstays of treatment for patients with advanced prostate cancer, says Gomella. Some institutional trials and other large national trials are looking at combining sipuleucel-T with other agents, such as enzalutamide (Xtandi).

An immuno-oncology drug with a novel antiandrogen treatment like enzalutamide may prove to be a benefit to patients with prostate cancer. Taking these advanced drugs and using them together in a long-term sequential fashion may prove to be beneficial, according to Gomella.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD